Campbell Newman Asset Management Has Trimmed Unitedhealth Group (UNH) Stake By $757,680; New Leaf Venture Partners Lifted By $1.40 Million Its Marinus Pharmaceuticals (MRNS) Holding

May 21, 2018 - By Marguerite Chambers

UnitedHealth Group Incorporated (NYSE:UNH) Logo

New Leaf Venture Partners Llc increased Marinus Pharmaceuticals Inc (MRNS) stake by 70% reported in 2017Q4 SEC filing. New Leaf Venture Partners Llc acquired 175,000 shares as Marinus Pharmaceuticals Inc (MRNS)’s stock declined 54.45%. The New Leaf Venture Partners Llc holds 425,000 shares with $3.47M value, up from 250,000 last quarter. Marinus Pharmaceuticals Inc now has $193.28 million valuation. The stock increased 2.58% or $0.12 during the last trading session, reaching $4.77. About 9,640 shares traded. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has risen 130.72% since May 21, 2017 and is uptrending. It has outperformed by 119.17% the S&P500.

Campbell Newman Asset Management Inc decreased Unitedhealth Group (UNH) stake by 4.06% reported in 2017Q4 SEC filing. Campbell Newman Asset Management Inc sold 3,444 shares as Unitedhealth Group (UNH)’s stock declined 0.93%. The Campbell Newman Asset Management Inc holds 81,300 shares with $17.92M value, down from 84,744 last quarter. Unitedhealth Group now has $237.82 billion valuation. The stock increased 1.16% or $2.84 during the last trading session, reaching $247.48. About 183,330 shares traded. UnitedHealth Group Incorporated (NYSE:UNH) has risen 32.42% since May 21, 2017 and is uptrending. It has outperformed by 20.87% the S&P500.

Investors sentiment increased to 0.96 in 2017 Q4. Its up 0.05, from 0.91 in 2017Q3. It is positive, as 51 investors sold UNH shares while 538 reduced holdings. 138 funds opened positions while 426 raised stakes. 806.07 million shares or 0.60% less from 810.94 million shares in 2017Q3 were reported. Gp One Trading Lp has 1,803 shares. Columbia Prtn L L C Invest Mgmt, Maryland-based fund reported 72,096 shares. State Of Tennessee Treasury Department accumulated 553,975 shares. Pinebridge Invs Lp has 139,337 shares for 0.79% of their portfolio. First National Bank & Trust Of Omaha has 0.04% invested in UnitedHealth Group Incorporated (NYSE:UNH). Oppenheimer Asset Mngmt reported 0.52% stake. Bridgeway Cap Management has 0.15% invested in UnitedHealth Group Incorporated (NYSE:UNH). Landscape Ltd Llc accumulated 0.03% or 1,628 shares. Private Inc owns 34,132 shares or 2.61% of their US portfolio. Stanley Mgmt Limited Com holds 1.83% or 16,180 shares in its portfolio. North Star Inv accumulated 44 shares or 0% of the stock. Manchester Capital Management Ltd Limited Liability Company holds 0.24% or 7,205 shares in its portfolio. Alphaone Svcs Ltd Liability reported 220 shares. Regions Corp invested 0.1% of its portfolio in UnitedHealth Group Incorporated (NYSE:UNH). Sumitomo Mitsui Asset reported 204,986 shares.

Among 27 analysts covering UnitedHealth Group (NYSE:UNH), 27 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. UnitedHealth Group had 88 analyst reports since September 2, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained UnitedHealth Group Incorporated (NYSE:UNH) on Tuesday, August 29 with “Buy” rating. The firm has “Buy” rating by Credit Suisse given on Thursday, July 13. The stock of UnitedHealth Group Incorporated (NYSE:UNH) has “Buy” rating given on Wednesday, August 16 by Jefferies. Cowen & Co maintained it with “Buy” rating and $22000 target in Friday, August 11 report. RBC Capital Markets maintained it with “Outperform” rating and $165 target in Wednesday, July 20 report. The firm earned “Buy” rating on Wednesday, October 18 by Bank of America. Credit Suisse maintained the shares of UNH in report on Wednesday, November 29 with “Buy” rating. The stock of UnitedHealth Group Incorporated (NYSE:UNH) earned “Buy” rating by Piper Jaffray on Tuesday, January 16. The firm earned “Buy” rating on Friday, November 20 by Mizuho. The rating was maintained by RBC Capital Markets with “Buy” on Wednesday, April 18.

Analysts await UnitedHealth Group Incorporated (NYSE:UNH) to report earnings on July, 17. They expect $3.03 EPS, up 23.17% or $0.57 from last year’s $2.46 per share. UNH’s profit will be $2.91 billion for 20.42 P/E if the $3.03 EPS becomes a reality. After $3.04 actual EPS reported by UnitedHealth Group Incorporated for the previous quarter, Wall Street now forecasts -0.33% negative EPS growth.

Since December 14, 2017, it had 0 buys, and 12 insider sales for $32.64 million activity. BURKE RICHARD T also sold $2.39M worth of UnitedHealth Group Incorporated (NYSE:UNH) on Wednesday, February 28. The insider HOOPER MICHELE J sold 10,000 shares worth $2.38 million. $3.28 million worth of UnitedHealth Group Incorporated (NYSE:UNH) was sold by Nelson Steven H on Thursday, March 15. 202 shares were sold by Shine Kenneth Irwin, worth $47,959 on Thursday, April 19. BALLARD WILLIAM C JR also sold $2.46M worth of UnitedHealth Group Incorporated (NYSE:UNH) on Tuesday, January 23. 22,184 shares were sold by RENFRO LARRY C, worth $5.08M. 5,820 shares valued at $1.40 million were sold by WILENSKY GAIL R on Thursday, January 18.

More recent UnitedHealth Group Incorporated (NYSE:UNH) news were published by: Bizjournals.com which released: “UnitedHealthcare forms group to reach Fayetteville area” on May 08, 2018. Also Investorplace.com published the news titled: “UnitedHealth Group Inc Rides High but Faces Challenges” on May 04, 2018. Businesswire.com‘s news article titled: “5 Million HouseCalls Provided to People Enrolled in UnitedHealthcare Medicare Advantage Plans” with publication date: May 21, 2018 was also an interesting one.

Investors sentiment decreased to 2 in 2017 Q4. Its down 0.80, from 2.8 in 2017Q3. It dropped, as 7 investors sold MRNS shares while 11 reduced holdings. 23 funds opened positions while 13 raised stakes. 20.53 million shares or 8.19% more from 18.97 million shares in 2017Q3 were reported. Deutsche State Bank Ag holds 0% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) for 416,215 shares. Massachusetts-based Adage Ptnrs Gru Limited Liability Company has invested 0.01% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). J Goldman And Limited Partnership holds 0% or 6,528 shares in its portfolio. Cormorant Asset Mgmt Lc holds 0.43% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) or 500,000 shares. New York-based Orbimed Advsrs Llc has invested 0.06% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Caxton Corporation invested 0.18% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). State Street accumulated 34,277 shares or 0% of the stock. Artal Group holds 200,000 shares. Quantbot Techs Ltd Partnership invested in 8,177 shares. Northern Tru Corp has 50,472 shares for 0% of their portfolio. 1,277 are owned by Citigroup Incorporated. 683 Capital Mngmt Limited Liability Company invested in 0.38% or 550,000 shares. Proshare Advsrs Limited Liability Company, Maryland-based fund reported 21,782 shares. New Leaf Venture Partners Ltd Limited Liability Company owns 425,000 shares. Granite Point Capital Mngmt LP accumulated 2.28M shares.

Among 5 analysts covering Marinus Pharmaceuticals (NASDAQ:MRNS), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Marinus Pharmaceuticals had 10 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was initiated by RBC Capital Markets on Thursday, December 17 with “Outperform”. The firm earned “Buy” rating on Wednesday, August 10 by Jefferies. The rating was maintained by Oppenheimer with “Outperform” on Wednesday, August 5. The stock of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has “Buy” rating given on Tuesday, November 17 by Jefferies. As per Tuesday, June 14, the company rating was maintained by Jefferies. The rating was maintained by Stifel Nicolaus on Tuesday, March 8 with “Buy”. As per Friday, October 30, the company rating was maintained by Oppenheimer. The stock has “Sector Perform” rating by RBC Capital Markets on Tuesday, June 14. The rating was initiated by Mizuho on Monday, March 19 with “Buy”. The rating was downgraded by Oppenheimer to “Perform” on Tuesday, June 14.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>